Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company developing antibody therapeutics for immune-mediated diseases. Its pipeline is built through acquisitions and in-licensing, with lead programs budoprutug and CLYM116 aimed at B-cell and APRIL biology across multiple autoimmune indications.

15.16

— Climb Bio, Inc.
	%
Lead antibody candidate: budoprutug	50% Clinical-stage anti-CD19 monoclonal antibody being developed for immune-mediated diseases.
Second antibody candidate: CLYM116	30% Anti-APRIL monoclonal antibody licensed for development and commercialization outside Greater China.
Clinical development programs	20% Preclinical and clinical work across pMN, ITP, SLE and other immune-mediated indications.

Climb Bio does not yet sell approved products, so its near-term 'customers' are clinical investigators, trial sites,...

Clinical investigators and trial sitesprimary
They run the company’s studies and generate the data needed to advance budoprutug and CLYM116.
Regulatorsprimary
FDA and other agencies evaluate the clinical package and determine whether the candidates can be approved.
Physicians treating autoimmune diseaseprimary
Future prescribers for pMN, ITP and SLE if the products reach market; they will choose based on efficacy and safety.
Third-party payorssecondary
Insurers and government payors will determine coverage and reimbursement, which will shape uptake.

Climb Bio is headquartered in the United States and conducts its development activities through a U.S...

•Headquartered in Wellesley Hills, Massachusetts, United States
•Clinical development and corporate functions are U.S.-based
•Budoprutug rights are worldwide except oncology
•CLYM116 rights exclude mainland China, Hong Kong, Macau and Taiwan
•No approved products and no disclosed product revenue yet

The company’s strategy is to build a focused pipeline in immune-mediated diseases using assets with clear biological...

Advance budoprutug in pMN, ITP and SLEshort-term

These indications have a strong mechanistic rationale and could validate the lead asset across multiple autoimmune markets.

Develop CLYM116 as a second B-cell targeted programmedium-term

Adds pipeline depth and diversifies the company beyond a single lead asset.

Secure external funding and partnershipsshort-term

The company has no product revenue and will need capital to fund trials and commercialization.

Climb Bio is exposed to the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need...

critical

Clinical development failure or delay

Budoprutug and CLYM116 are still in development and may not show sufficient safety or efficacy.

Scope: Lead programs in pMN, ITP and SLE
Materiality: high

high

Need for additional capital

The company has no product revenue and expects continued operating losses, so funding needs are ongoing.

Scope: Equity dilution or unfavorable financing terms
Materiality: high

high

Competitive pressure in autoimmune disease

Large pharma and biotech peers may launch superior or earlier therapies, limiting market share and pricing.

Scope: Immune-mediated disease markets
Materiality: high

medium

Manufacturing and supply dependence on CDMOs

The company does not own manufacturing facilities and relies on third parties for clinical and future commercial supply.

Scope: Nonclinical and clinical supply chain
Materiality: medium

Research and development accruals

Affects operating loss, accrued liabilities and period-to-period comparability

Stock-based compensation

Can materially increase non-cash operating expense

Impairment and valuation of acquired/licensed assets

Could affect intangible assets and future earnings

Climb Bio, Inc.

Clinical development failure or delay

Need for additional capital

Competitive pressure in autoimmune disease

Manufacturing and supply dependence on CDMOs

Inmune Bio, Inc.

Climb Global Solutions, Inc.

MUSTANG BIO, INC.

Upstream Bio, Inc.

Cullinan Therapeutics, Inc.

GRI Bio, Inc.